Who they are now
A lab in Basel where rejected molecules get a second life.
It is late 2024, and a wire transfer just landed. EQT Life Sciences has led a Series B extension that pushes Noema Pharma's round to CHF 130 million - about USD 147 million. The money is not for a logo refresh or a glass headquarters. It is fuel for four clinical trials, each pointed at a nervous-system condition that most of the industry decided was too small, too hard, or too unglamorous to bother with.
Noema is a clinical-stage biotech, which is a polite way of saying it has no products on the market and a lot of conviction. Thirty-four people. Three Phase 2 programs running at once. And a pipeline built almost entirely from molecules that a far larger company - Roche - chose not to carry forward. That last part is the whole story, so hold onto it.
Most biotechs hunt for the next blockbuster. Noema went looking for the patients everyone forgot.
The Noema thesis, in one line
The problem they saw
The brain is hard. So the brain gets skipped.
Central nervous system drugs are notoriously difficult. Trials are long, endpoints are slippery, and the failures are expensive and public. When a rare neurological condition has only a few thousand patients, the math gets worse. A drug giant runs the spreadsheet, the spreadsheet shrugs, and a promising compound goes into a drawer.
That drawer is where Noema went shopping. Seizures in tuberous sclerosis complex. Stabbing facial pain in trigeminal neuralgia. The tics of Tourette syndrome. The hot flashes and CNS-mediated symptoms of menopause. Different diseases, same nervous system, and the same shared problem: real people, real suffering, and not nearly enough companies willing to do the work.
"Shelved" is not a synonym for "failed." It usually just means "someone else was busy."
On the economics of overlooked diseases
The founders' bet
Start with assets that already worked - then point them somewhere new.
Noema was created in 2019 by Sofinnova Partners, the venture firm, around a specific insight. George Garibaldi, Roche's former head of neuroscience product development, knew exactly which compounds had cleared early hurdles before being set aside. Co-founder Luigi Costa took the CEO chair and built the company around four of them, in-licensed straight from Roche.
It is a contrarian move dressed up as a conservative one. Instead of inventing a molecule and praying it survives a decade of trials, Noema started with chemistry that had already been tested in humans - and aimed it at the diseases that needed it most. Less moonshot, more matchmaking.
The bet was never "can we make a new drug." It was "can we put a known drug where it finally matters."
Reading between the founding documents
In June 2023, the company handed the wheel to Ilise Lombardo, M.D. - 25-plus years in CNS, and a co-founder of Arvelle Therapeutics, the European CNS company that Angelini Pharma bought for roughly a billion dollars in 2021. She had built a launch-ready neuro company once. Noema asked her to do it again, this time from the molecule up.
The proof
Conviction is cheap. A syndicate is not.
You can tell a lot about a biotech by who writes the checks. Noema's cap table reads like a who's-who of specialist life-science money: Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, UPMC Enterprises, and now EQT Life Sciences. These are investors who read clinical data for a living, and they kept coming back.
Three Phase 2 trials running at once is not a press release. It is a payroll, a protocol, and a deadline.
On what "clinical-stage" actually costs
UPMC Enterprises is the telling one - the venture arm of a major U.S. health system, betting on a Swiss company that treats the nervous system. That is not a financial investor chasing a markup. It is an operator who sees these patients in clinics and wants the drugs to exist.
The mission
"Superior clinical benefit" is the whole pitch.
Noema describes its mission plainly: advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications. No talk of disrupting anything. The ambition is narrower and harder - make a drug that works better than what a patient with trigeminal neuralgia or Tourette syndrome has today, which in many cases is very little.
The opposite of a blockbuster is not a failure. Sometimes it's the only drug a few thousand people have ever had.
Why orphan indications are worth the trouble
It is faintly ironic that a company built on other people's discarded chemistry might end up defining its own category. But that is how overlooked markets work - the field clears out, and whoever stays gets to write the rules.
Why it matters tomorrow
2025 is the year the bet gets graded.
Return to that late-2024 wire transfer. The money is in. The trials are running. And somewhere in 2025, data starts coming back - the readouts that decide whether four molecules Roche set aside were genuinely overlooked, or set aside for a reason.
If the data holds, Noema becomes proof that the industry's blind spots are also its opportunities, and that a lean Basel team can do what a giant chose not to. If it doesn't, the company will have still done something the rest of the field avoided: it showed up for patients nobody else would. Either way, the drawer Roche closed in 2019 is open again - and this time someone is actually reading what's inside.
The diseases everyone filed away are still here. Noema's whole reason to exist is to un-file them.
The closing argument
